BriaCell Therapeutics Corp. BCTX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001610820

None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $23.6M
Warnings	short runway, thin data not computable: dilution, degenerate inputs, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Oct 28, 2026 1 days before the rescan; latest periodic filing 10-K received Oct 28, 2026
Last close	$3.50 2026-10-28; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Oct 28, 2026

Therapeutics Corp. ("Briacell" or the "Company") is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body's own immune system to recognize and destroy cancer cells. The Company is currently advancing its Bria-IMT? targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab®) in a pivotal1 Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612). Bria-IMT? is currently under Fast Track Designation by the U.S.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 15.0						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

one or more required annual facts are missing						
Accruals ratio	(27.6%)	(6.6%)		15.0	805	2026-07-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 58.5						
Twelve-month failure probability	not computable	0.07%				
firm-wide XBRL shares cannot be assigned to one ticker class						
Altman Z double-prime	not computable	(0.33)				
one or more required annual facts are missing						
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
interest expense must exceed $100,000						
Current ratio	2.76x	2.94x		58.5	832	2026-07-31
Growth and financing, sleeve percentile 62.1						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	not computable	37.1%				
required facts have no common fiscal period end						
Asset growth, three years	(4.6%)	2.1%		62.1	697	2026-07-31
Net share issuance, one year	not computable	2.5%				
firm-wide XBRL shares cannot be assigned to one ticker class						

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 4.1 months
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-28 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(67.4%)	7.7%	7
Distance from 52-week high	(73.8%)	(27.7%)	11
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.27	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.33)	(0.14)	7

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-07-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$9.9M
Operating cash flow, four quarters	-$28.7M
Months of runway	4.1
Days since last periodic filing	1 (10-K received Oct 28, 2026)
Median daily dollar volume, 63 sessions	$338,088

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$34.9M	2026-07-31	2026-10-28	10-K	26-049041
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$28.7M	2026-07-31	2026-10-28	10-K	26-049041
3	assets	us-gaap:Assets	$23.6M	2026-07-31	2026-10-28	10-K	26-049041
4	assets	us-gaap:Assets	$21.6M	2025-07-31	2026-10-28	10-K	26-049041
5	operating income	us-gaap:OperatingIncomeLoss	-$15.3M	2022-07-31	2023-10-25	10-K	23-038298
6	interest expense	us-gaap:InterestExpense	$979	2022-07-31	2023-10-25	10-K	23-038298
7	current assets	us-gaap:AssetsCurrent	$22.0M	2026-07-31	2026-10-28	10-K	26-049041
8	current liabilities	us-gaap:LiabilitiesCurrent	$8.0M	2026-07-31	2026-10-28	10-K	26-049041
9	assets	us-gaap:Assets	$5.9M	2024-07-31	2025-10-16	10-K	25-018212
10	assets	us-gaap:Assets	$27.2M	2023-07-31	2024-10-29	10-K	24-042743

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.